

1 **5-Fluorouracil loaded Eudragit fibers prepared by electrospinning**

2
3 U. Eranka Illangakoon,¹ Deng-Guang Yu,^{2*} Bilal S. Ahmad,¹ Nicholas P. Chatterton,^{3*} and
4 Gareth R. Williams^{1*}

5
6 ¹ UCL School of Pharmacy, University College London, 29 – 39 Brunswick Square, London,
7 WC1N 1AX, UK

8 ² School of Materials Science & Engineering, University of Shanghai for Science and
9 Technology, Shanghai 200093, China.

10 ³ Department of Life, Health & Chemical Sciences, The Open University, Walton Hall, Milton
11 Keynes, MK7 6AA, UK.

12
13 * Authors for correspondence. Email: ydg017@usst.edu.cn (DGY);
14 nicholas.chatterton@open.ac.uk (NPC); g.williams@ucl.ac.uk (GRW). Tel: +86 21 5527 0632
15 (DGY); +44 (0) 1908 655488 (NPC); +44 (0) 207 753 5868 (GRW). Fax: +44 (0) 20 7753 5942
16 (GRW).

19

20 **Abstract**

21 A series of 5-fluorouracil (5-FU) loaded core/shell electrospun fibers is reported. The fibers
22 have shells made of Eudragit S100 (ES-100), and drug-loaded cores comprising
23 poly(vinylpyrrolidone), ethyl cellulose, ES-100, or drug alone. Monolithic 5-FU loaded ES-100
24 fibers were also prepared for comparison. Electron microscopy showed all the fibers to have
25 smooth cylindrical shapes, and clear core-shell structures were visible for all samples except
26 the monolithic fibers. 5-FU was present in the amorphous physical form in all the materials
27 prepared. Dissolution studies showed that the ES-100 shell was not able to prevent drug
28 release at pH 1.0, even though the polymer is completely insoluble at this pH: around 30 to
29 80 % of the maximum drug release was reached after 2h immersion at pH 1.0. These
30 observations are ascribed to the low molecular weight of 5-FU permitting it to diffuse
31 through pores in the ES-100 coating, and the high acid solubility of the drug providing a
32 thermodynamic impetus for this to happen. In addition, the fibers were observed to be
33 broken or merged following 2h at pH 1.0, providing additional escape routes for the 5-FU.

34

35 **Keywords**

36 Coaxial electrospinning; Eudragit; 5-Fluorouracil; colon-targeted drug delivery

37

38 **Chemical compounds studied in this article**

39 5-Fluorouracil (PubChem CID: 3385)

40

41

42 **1. Introduction**

43 Electrospinning is a facile technique which has been widely explored in pharmaceuticals
44 (Chakraborty et al., 2009; Williams et al., 2012). In its simplest embodiment, a polymer is
45 dissolved in a volatile solvent and ejected from a syringe fitted with a metal needle
46 (spinneret) towards a metal collector at a controlled rate. The application of a high (kV)
47 voltage between the spinneret and the collector causes the rapid evaporation of solvent,
48 and results in the formation of nanoscale one-dimensional polymer fibers on the collector. If
49 an active pharmaceutical ingredient (API) is co-dissolved with the polymer then drug-loaded
50 fibers can be prepared, and these have been investigated for use as a broad range of drug
51 delivery systems including fast-dissolving (Balogh et al., 2015; Li et al., 2013a; Li et al.,
52 2013b; Nagy et al., 2010; Samprasit et al., 2015), sustained release (Chen et al., 2010b;
53 Okuda et al., 2010; Xie and Wang, 2006; Xu et al., 2011), pulsatile release (Kaassis et al.,
54 2014), and targeted release formulations (Abdullah et al., 2011; Shen et al., 2011; Yu et al.,
55 2014). In recent years, researchers have developed increasing complex electrospinning
56 experiments, and the use of coaxial electrospinning (which uses a concentric spinneret, with
57 one needle nested inside another) to prepare core/shell structures has been very widely
58 reported (Chakraborty et al., 2009; Chen et al., 2010a; Llorens et al., 2015).

59

60 A common way to achieve targeted drug release is to use a pH-sensitive polymer to ensure
61 that the API is freed only in a certain part of the gastro-intestinal tract. An enteric coating to
62 a tablet or capsule to preclude drug release in the stomach is perhaps the simplest and most
63 commonly employed embodiment of this. A range of pH-sensitive polymers exists, such as
64 alginates, chitosan, poly(methacrylic acid-grafted-poly(ethylene glycol)) (Lowman et al.,
65 1999), or poly(methacrylic acid-*co*-*N*-vinylpyrrolidone) (Carr and Peppas, 2010). One such
66 family of materials, the Eudragit methacrylate polymers, has been widely used in the
67 formulation of oral dosage forms including as tablet coatings or tablet matrices, and to
68 prepare microspheres and nanoparticles for controlled drug delivery in the gastro-intestinal
69 (GI) tract (Krishnaiah et al., 2002; Momoh et al., 2014; Varshosaz et al., 2015). Eudragit L100,
70 L100-55 and S100 are specifically designed for targeting the lower parts of the GI tract;
71 these fibers are insoluble at low pH, dissolving only at pH 6.0, 5.5, or 7.0 respectively.

72

73 Shen et al (Shen et al., 2011) were the first to fabricate electrospun Eudragit fibers, making
74 materials of the Eudragit L100-55 (EL-100-55) polymer and diclofenac sodium. *In*
75 *vitro* dissolution tests revealed that the fibers had pH-dependent release profiles, with very
76 limited (less than 3%) diclofenac release at pH 1.0, but sustained and complete drug release
77 over 6 hours at pH 6.8. A second study prepared analogous fibers using coaxial spinning with
78 a mixture of ethanol and dimethylacetamide as the sheath fluid, which was reported to yield
79 better quality fibers (Yu et al., 2014); again, very little drug was released in the acidic
80 medium (< 5 %). Similar results have been seen for systems comprising EL-100-55 and
81 ketoprofen (Yu et al., 2013b), heligid (Yu et al., 2013a), and mebeverine hydrochloride
82 (Illangakoon et al., 2014). In other work, Aguilar *et al.* made blend fibers of EL-100-55 and
83 poly(urethane) with paclitaxel, and saw very little release at pH 4 but much greater release
84 at pH 6 (Aguilar et al., 2015). Eudragit S100 (ES-100) fibers containing uranine and nifedipine
85 have been shown to give rapid release of the incorporated drugs at pH 6.8, but no *in vitro*
86 studies were performed at lower pH values (Hamori et al., 2014). Eudragit has also been
87 used to coat electrospun fibers (Nista et al., 2013).


88

89 Some authors have also reported successful colon targeting using core/shell fibers made
90 with a ES-100 shell and an ethyl cellulose core (Xu et al., 2013). It appears, however, that in
91 some cases – most likely because of the very high surface-area-to-volume ratio of
92 electrospun fibers – drug release can be seen at low pH even when the polymer filament is
93 not soluble. Karthikeyan and co-workers generated mixed fibers of zein and ES-100 loaded
94 with pantoprazole and aceclofenac and found that after 2 h immersion 0.1 N HCl, while only
95 6 % of the former was released, some 25 % of the latter was freed into solution (Karthikeyan
96 et al., 2012).

97

98 In this work, we were interested in preparing pH-sensitive electrospun drug delivery
99 systems for the anti-cancer drug 5-fluorouracil (5-FU; Figure 1). 5-FU has a very low
100 molecular weight, and is very soluble in acidic media. It has been prescribed for over 55
101 years, and is widely used for the treatment of colorectal, breast, gastrointestinal, and
102 ovarian cancers (Rejinold et al., 2011). The drug is usually administered intravenously (due
103 to its poor water solubility) or topically as an ointment, especially in the case of skin cancer.

104 Here we sought to develop systems to deliver 5-FU specifically to the lower reaches of the
105 GI tract.



106
107 **Figure 1.** The chemical structure of 5-FU.
108

109 **2. Materials and methods**

110 **2.1 Materials**

111 Eudragit S100 (Mw = 125,000 Da) was a gift from Evonik GmbH (Darmstadt, Germany).
112 Poly(vinylpyrrolidone) (PVP) K60 (Mw = 360,000 Da) was purchased from the Shanghai
113 Yunhong Pharmaceutical Aids and Technology Co., Ltd. (Shanghai, China). Ethyl cellulose (6
114 mPa·s to 9 mPa·s) was obtained from the Aladdin Chemistry Co., Ltd (Shanghai, China). 5-FU
115 was purchased from Sigma–Aldrich (Gillingham, UK). Basic fuchsin, N,N-dimethylformamide
116 (DMF), and anhydrous ethanol were provided by the Sinopharm Chemical Reagent Co., Ltd.
117 (Shanghai, China). All other chemicals and reagents were of analytical grade, and were used
118 as supplied. Water was distilled prior to use.

119

120 **2.2 Electrospinning**

121 A 13 % w/v Eudragit S100 (ES-100) solution was prepared in a mixture of ethanol and N,N-
122 dimethylformamide (DMF; 8:2 v/v) and used as the sheath solution. A 10 % w/v solution of
123 5-FU in DMF was also prepared, and used to generate four different core solutions: 1 mL of
124 the 5-FU solution was combined with 1 mL of a polymer solution, as detailed in Table 1. To
125 aid observation of the electrospinning process, 0.2 mg/mL of basic fuchsin was added to the
126 S3 solution.

127

128

129

130

131

132

133

Table 1. The compositions of the solutions used for coaxial electrospinning.

ID	Core solution prepared from ^a	Core solution composition (w/v)	Sheath solution (w/v)
S1	6 % PVP in ethanol and 10 % 5-FU	3 % PVP and 5 % 5-FU	13 % ES-100
S2	20 % ethyl cellulose in ethanol and 10 % 5-FU	10 % ethyl cellulose and 5 % 5-FU	13 % ES-100
S3	5 % ES-100 in ethanol/DMF and 10 % 5-FU	2.5 % ES-100 and 5 % 5-FU	13 % ES-100
S4	DMF and 10 % 5-FU	5 % 5-FU	13 % ES-100
S5	13 % ES-100 and 5 % FU in ethanol/DMF (8/2 v/v)	13 % ES-100 and 5 % 5-FU	Ethanol

134

^a All % ages are as w/v, and the 5-FU solution was prepared in DMF. Core solutions were prepared by combining 1 mL of the appropriate polymer solution with 1 mL of the 5-FU solution for S1 – S4.

135

136

137

Coaxial electrospinning was performed on a setup comprising two syringe pumps (KDS100 and KDS200, Cole-Parmer, Vernon Hills, IL, USA) and a high voltage power supply (ZGF 60Kv/2mA, Shanghai Sute Corp., Shanghai, China). A concentric spinneret was employed for the electrospinning process: the outer needle had an internal diameter (I.D.) of 1.2 mm, and the inner needle an I.D. of 0.3 mm. The electrospinning processes were recorded using a digital camera (PowerShot A490, Canon, Tokyo, Japan). Following a series of optimization experiments, the applied voltage was fixed at 14.5 kV, the core fluid flow rate at 0.1 mL / h (S1 and S2) or 0.2 mL / h (S3, S4, and S5), and the sheath fluid rate at 1.5 mL / h (S1/S2) or 3 mL / h (S3/S4/S5). Fibers were collected on a flat piece of aluminium foil placed 12 cm from the spinneret. All experiments were performed under ambient conditions (25 ± 2 °C; 57 ± 6% relative humidity).

148

149 **2.3 Characterization**

150 **2.3.1 Electron microscopy**

151

The morphology of the fibers was examined using an S-4800 field-emission scanning electron microscope (FESEM, Hitachi, Tokyo, Japan). The average fiber diameter was determined by measuring the fibers (n > 50) in SEM images, using the ImageJ software (National Institutes of Health, Bethesda, MD, USA). Transmission electron microscope (TEM) images of the samples were obtained on a JEM-3000F HR field emission TEM (JEOL, Tokyo, Japan). Fiber samples were collected by fixing a lacey carbon-coated copper grid to the collector and electrospinning directly on to this.

158

159 **2.3.2 Physical form assessment**

160 X-ray diffraction (XRD) patterns were recorded on a D8 Advance instrument (Bruker,
161 Billerica, MA, USA) using Cu K α radiation at 40 kV and 25 mA. Differential scanning
162 calorimetry (DSC) analyses were carried out using a DSC Q2000 calorimeter (TA instruments,
163 New Castle, DE, USA). Sealed samples were heated at 10 °C /min from 40 to 300 °C under a
164 50 mL / min flow of nitrogen.

165

166 **2.3.3 IR spectroscopy**

167 Attenuated total reflectance Fourier transform infrared (FTIR) analysis was carried out on a
168 Spectrum 100 FTIR spectrometer (PerkinElmer, Waltham, MA, USA). The scanning range was
169 650–4000 cm⁻¹, and the resolution was set at 1 cm⁻¹.

170

171 **2.3.4 In vitro dissolution testing**

172 Drug release was quantified using a USP-II test performed on automated apparatus (PTWS
173 instrument, Pharma Test, Hainburg, Germany). 50 mg of the fiber mat was inserted into a
174 size 0 gelatine capsule (SpruytHillen, IJsselstein, Holland) which was in turn loaded into a
175 metal sinker. Each capsule was placed in a vessel containing 750 ml of 0.1 N HCl. After 120
176 min, 250 ml of 0.2 M tri-sodium phosphate (equilibrated to 37 ± 0.5 °C) was added to each
177 vessel, and the pH of the solution was adjusted to pH 6.8 using 2 N HCl. The vessel was
178 continuously stirred with a paddle at 50 rpm, and throughout the experiment the
179 temperature of the dissolution medium was maintained at 37 ± 0.5 °C. The 5-FU released
180 was assayed at 266 nm using an inline UV spectrophotometer (Cecil 2020, Cecil Instruments
181 Ltd., Cambridge, UK). Data were processed using the Icalis software (Icalis Data Systems Ltd,
182 Wokingham, UK). Experiments were performed in triplicate and data are reported as mean
183 ± S.D. To observe the fibers after 2h immersion at pH 1.0, a separate set of experiments was
184 performed in which 7 – 8 mg of fibers was placed in 10 mL of 0.1 N HCl and incubated at 37
185 °C for 2 h. The fiber mat was then recovered, dried, and imaged by SEM.


186

187 **3. Results**

188 **3.1 The electrospinning process**

189 Photographs of the electrospinning process for S3 are given in Figure 2. When no voltage
190 was applied, it is evident that the core and sheath solutions did not mix when they came

191 together. This indicates that the solution parameters were correctly tuned to yield a
192 core/shell structure. When the applied voltage was increased to 14.5 kV a straight thinning
193 jet was ejected from the compound Taylor cone; this then undergoes bending and whipping
194 motions forming loops of increasing size (Figure 2(b) and (c)).



204 **Figure 2.** Photographs of the S3 coaxial electrospinning process. **(a)** the liquid droplet at 0 kV; **(b)** the
205 compound Taylor cone showing jets ejecting from the tip at 14.5 kV; **(c)** the bending and whipping movement
206 of the jet at 14.5 keV; and, **(d)** the division of the jet at 16 kV.

208 A further increase in the applied voltage to 16 kV led to branching of the spinning jet, giving
209 two bending and whipping instability regions. Branching of the spinning jet is a complex
210 phenomenon and may give rise to separation of the shell and core parts of the fibers.
211 Therefore, the applied voltage was set as 14.5 kV for all subsequent electrospinning
212 processes.

214 3.2 Fiber morphology

215 SEM images of the fibers produced are given in Figure 3. The fibers have smooth surfaces
216 and comprise uniform structures without any ‘beads-on-a-string’ morphology visible. There
217 is no evidence for any particles or phase separation present, indicating that the multiple
218 components of the formulations are homogeneously mixed. Some precipitation of 5-FU was
219 observed during the solution preparation process for S2, but no drug crystals can be seen in
220 the fibers.

224
225
226
227
228
229
230
231
232
233
234
235




Figure 3. SEM images of the fibers. (a) S1; (b) S2; (c) S3; (d) S4; (e) S5; and, (f) the ends of the S3 fibers.

236
237
238
239
240

The fiber diameters are listed in Table 2. It can be seen that all the fibers are around 1 μm in size, with the fibers containing S100 and 5-FU solution only as the core being larger than the PVP and EC containing samples.

Table 2: The diameters of the Eudragit-based fibers.

Formulation	Core	Shell	Fiber diameter / nm
S1	PVP / 5-FU	ES-100	899 ± 208
S2	EC / 5-FU	ES-100	848 ± 215
S3	ES-100 / 5-FU	ES-100	1275 ± 383
S4	5-FU	ES-100	1033 ± 233
S5	ES-100/5-FU	-	873 ± 232

241
242
243
244
245
246

TEM was employed to study in more detail the structures of the fibers, and the results are presented in Figure 4. S1, S2, S3 and S4 possess distinct core-shell structures. The S5 fibers, in contrast, do not show any core-shell structure; this is as expected, since the shell fluid for S5 comprised purely a solvent.

247
248
249
250
251
252
253
254
255
256
257




Figure 4. TEM images of (a) S1; (b) S2; (c) S3; (d) S4; and, (e) S5.

258

259 3.3 Physical form

260 The physical form of the fiber components was studied by X-ray diffraction (XRD) and
261 differential scanning calorimetry (DSC). The resultant data are shown in Figure 5.

262




Figure 5. (a) XRD and (b) DSC data for the electrospun fibers and raw materials.

270
271

272 From the diffraction data, it is clear that 5-FU is a crystalline material with numerous
273 characteristic reflections present in its XRD pattern. The polymers ES-100, PVP and EC
274 display only broad haloes in their patterns, consistent with their existence as amorphous
275 materials. In all cases, the XRD patterns of the composite fibers do not show any Bragg
276 reflections, only the broad humps typical of amorphous materials.

277

278 In DSC, 5-FU shows a sharp endothermic melting peak at 287 °C, in good agreement with
279 the literature value (Krishnaiah et al., 2002). The DSC spectrum of Eudragit S100 showed a
280 broad endothermic band between 55 and 100 °C, which can be ascribed to the loss of
281 absorbed and adsorbed water. This is followed by a second endothermic band which begins

282 at around 150 °C, in accordance with the literature (Chawla et al., 2012; Hu et al., 2012).
283 PVP also shows a broad dehydration endotherm between 55 and 125 °C. The EC
284 thermogram contains no distinct features.

285


286 The DSC traces of all the fibers do not contain a 5-FU melting endothermic peak, thus
287 demonstrating the absence of crystalline material in the formulations. This is consistent with
288 the XRD data. All the fiber formulations exhibit a shallow endothermic peak below 100 – 150
289 °C, which is attributed to the loss of water.

290

291 3.4 IR spectroscopy

292 IR spectra of the raw materials and electrospun fibers are depicted in Figure 6.

293



294

295 **Figure 6.** FTIR spectra of the fibers and raw materials.

296

297 The IR spectrum of pure 5-FU shows two carbonyl (C=O) stretching at 1720 and *ca.* 1645
298 cm⁻¹ (Gao et al., 2007), a C-N stretch at 1243 cm⁻¹ and a C-F stretch at 995 cm⁻¹. The broad
299 stretch between 3150- 2800 cm⁻¹ is due to C-H and N-H stretching. The spectrum of ES-100
300 displays characteristic bands of methyl and methylene C-H stretching vibrations at 2997 and
301 2952 cm⁻¹, a strong band because of carbonyl groups at 1724 cm⁻¹ (C=O stretch) and two
302 bands because of ester linkages (C-O-C stretches) at 1257 and 1148 cm⁻¹. In the spectra of
303 the fibers, the most intense peaks from ES-100 are visible at 1720 – 1724 cm⁻¹ (C=O stretch)
304 and a second peak can be seen at 1148 - 1150 cm⁻¹ due to C-O-C stretching. The S1 fibers
305 additionally show a strong peak at 1650 cm⁻¹, which may arise either from 5-FU or from the
306 PVP comprising its core. The other fibers show a shoulder to the Eudragit peak at 1720 –
307 1724 cm⁻¹, which is expected to correspond to a 5-FU carbonyl stretch; this is particularly


308 marked in S5. The peak positions are little changed in the fibers from the raw materials. The
309 distinct 5-FU phonon vibrations below 1000 cm^{-1} (e.g. at 750 cm^{-1}) do not appear to be
310 present, but the picture is confused by the fact that ES-100 has peaks at similar
311 wavenumbers. All in all, these data are consistent with the XRD and DSC data, indicating a
312 molecular dispersion of 5-FU in the polymer carriers.

313

314 3.5 *In vitro* drug release

315 The *in vitro* drug release profiles of the different fibers are given in Figure 7. The S2 fibers
316 were not studied in this assay, because the observation of precipitates in the
317 electrospinning process led to concern about their homogeneity.

318



319

320 **Figure 7.** *In vitro* 5-FU release from the fiber formulations. Experiments were performed in triplicate, and the
321 data shown as mean \pm S.D. 100% release is defined as the point at which maximum drug release was observed.
322

323 These results are unexpected. Since ES-100 is insoluble at pH 1.0, it would intuitively be
324 expected that the drug would release very slowly under these conditions. However, it is
325 clear that in all cases 5-FU release happens rather rapidly, even at such a low pH. The single-
326 fluid S5 fibers release their drug load most quickly, followed by S4 (for which the core fluid
327 was a 5-FU solution only), S3 (ES-100 core), and S1 (PVP core). When the pH is raised to 6.8,
328 a second burst of release is seen for all the fibers, with S3, S4 and S5 then very rapidly
329 reaching maximum drug release. S1, possibly counter-intuitively given the very high
330 solubility of PVP, gives a sustained release of drug over the remaining 6h of the experiment.

331

332 The rapid release from S5 at pH 1.0 can be explained by a combination of two factors. First,
333 5-FU is a low molecular weight and basic drug, and is very soluble at low pH. Second, the

334 very high surface-area-to-volume ratio of the fibers will result in a large amount of 5-FU
335 being present at the fiber surfaces. This surface drug will be freed rapidly into solution. 5-FU
336 from further inside the fibers may also be able to diffuse out through pores created by
337 earlier departing drug molecules. It was observed that after 2h of immersion in 750 mL of
338 the acid medium, the S5 fiber mat had virtually completely disintegrated, presumably as a
339 result of the loss of a significant amount of its drug loading causing the fibers to collapse and
340 separate.

341

342 The rapid release of drug from the core/shell fibers is more puzzling. Although the fibers
343 appear to have clear core/shell structures from TEM images, with a clear interface between
344 these two compartments of the fibers, it may be that some mixing of the core and shell
345 solutions occurred, resulting in some 5-FU being present at the surface of the fibers. The
346 dissolution of this could yield pores through which the remaining drug in the core could
347 escape. This process is somewhat more arduous than the freeing of surface drug into
348 solution, and thus takes longer, leading to slower release from the core/shell fibers. Pores
349 through which drug molecules could escape from the fibers could also be created by
350 swelling of the S100 shell and the permeation of water into the centre of the fibers.

351

352 To obtain more insight into the drug release mechanism, the fibers were imaged after 2 h
353 immersion in 0.1 N HCl (see Figure 8).

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368




Figure 8. SEM images of the fibers recovered after 2 h immersion in HCl. (a) S1; (b) S2; (c) S3; (d) S4; and, (e) S5.

369 The fibers S2, S3, S4 and S5 appear largely unaffected by the acid treatment, as would be
370 expected given the insolubility of Eudragit at this pH. However, for S3, S4 and S5, it is clear
371 that there are a number of broken fibers present. The breaking of the fibers will aid the
372 release of 5-FU, since it will expose sections of the core to the release medium. However,
373 the area revealed by such breakages is relatively small, and thus this is not expected to be a
374 major factor.

375

376 In contrast, the S1 fibers are no longer visible as individual entities, having merged and
377 formed an irregular and continuous sheet. This must be ascribed to the very high
378 hydrophilicity of the PVP core in these fibers: water ingress through small pores in the
379 Eudragit shell must have been absorbed by the PVP, causing it to swell and the fibers to
380 “burst”, losing their integrity. The formation of this agglomerate will reduce the surface-
381 area-to-volume ratio of the fiber mat, and can perhaps explain the sustained release
382 observed for the S1 material. Attempts to model the first stage of drug release, in the pH 1.0
383 buffer, were undertaken using the Peppas model (Ritger and Peppas, 1986); the resultant
384 plots were decidedly non-linear, showing that simple Peppas-type release kinetics are not
385 applicable to these systems.

386

387

388 **4. Discussion**

389 In this work, a family of core/shell fibers based on Eudragit S100 has been prepared and
390 fully characterised. We find that the fibers have very distinct core/shell structures, but that
391 even when there is no drug in the shell release at pH 1 is nevertheless rapid. In contrast to
392 these findings, previous reports (Aguilar et al., 2015; Illangakoon et al., 2014; Shen et al.,
393 2011; Yu et al., 2014) have shown that monolithic Eudragit fibers can preclude drug release
394 at acidic pHs. In these studies, a range of APIs were used; the properties of these, together
395 with those of 5-FU, are summarised in Table 3. Other than the data reported in this work,
396 only the API aceclofenac showed appreciable release at low pH (Karthikeyan et al., 2012).

397

398

399

400

401 **Table 3:** A summary of the literature data on electrospun Eudragit fibers where dissolution at low pH has been
 402 explored, and the APIs incorporated.

API	Reference	pKa	RMM	Polymer(s) in fiber
Diclofenac sodium	(Shen et al., 2011; Yu et al., 2014)	4.1	318	EL-100-55
Mebeverine hydrochloride	(Illangakoon et al., 2014)	8.1	466	EL-100-55
Paclitaxel	(Aguilar et al., 2015)	10.9	854	EL-100-55 / PU ^a
Aceclofenac	(Karthikeyan et al., 2012)	4.7	354	ES-100 / zein
Pantoprazole	(Karthikeyan et al., 2012)	4.0	383	ES-100 / zein
Ketoprofen	(Yu et al., 2013b)	4.45	254	EL-100-55
Helicid	(Yu et al., 2013a)	-	284	EL100-55
5-FU	This work	8.1	130	ES-100

403 ^a PU = polyurethane.

404

405 From a consideration of the data in Table 3, it is not completely clear why high levels of 5-FU
 406 and aceclofenac release are seen at low pH, while for all the other APIs only minimal release
 407 is seen. It is not possible to make completely clear comparisons because of differences in
 408 the polymer systems used. We have prepared monolithic EL-100-55 fibers with 5-FU and
 409 found substantial release at pH 1.0 (data not shown), so we do not believe that the use of
 410 EL-100-55 or ES-100 is a major contributory factor to the different behaviours: both are
 411 after all insoluble at pH 1.0. Ketoprofen and diclofenac are acidic drugs, and thus the fact
 412 that they do not release from EL-100-55 fibers at pH 1.0 can be attributed to their low
 413 solubility at this pH. Helicid is non-ionisable and poorly soluble, and thus its lack of release
 414 at low pH is also understandable. Paclitaxel has a very high molecular weight, and very low
 415 solubility, so again here the data are intuitively understandable. In contrast, 5-FU is basic,
 416 and releases substantially at low pH from monolithic ES-100 fibers presumably owing to its
 417 high solubility in acidic conditions. However, mebeverine, another basic drug, does not.
 418 Looking at the drug properties, the major factor that stands out is the very low molecular
 419 weight of 5-FU. We thus believe that it is a combination of small molecule size and high acid
 420 solubility which together cause the large amounts of 5-FU release observed from monolithic
 421 ES-100 fibers at low pH. The low molecular weight of the drug is expected to aid it diffusing
 422 through pores into the fibers and into solution, a situation encouraged by the favourable
 423 resultant dissolution energy.

424

425 It should be noted that the results obtained by Karthikeyan *et al.* are contradictory to this
426 explanation. These authors found that aceclofenac (acidic) and pantoprazole (basic) behave
427 differently, with the acidic drug releasing to a greater extent (Karthikeyan et al., 2012). This
428 may be because of the inclusion of zein in their monolithic fibers, and/or suggests that the
429 picture is more complex and the intermolecular interactions between the polymer matrix
430 and the drug also need to be considered, even with the high surface-area-to-volume ratios
431 seen with electrospun fibers.

432

433 Considering the core/shell fibers, significant amounts of 5-FU release are still seen at low
434 pH. This may arise for two reasons. It may be there is some mixing of the core and shell
435 solutions during electrospinning (even though clear compartments are observed by TEM),
436 leading to the presence of 5-FU at the surface. This can dissolve easily, leading to pores in
437 the shell through which the 5-FU can escape. Alternatively, it may be that 5-FU from the
438 core can simply diffuse through pores already existing in the shell. The loss of fiber
439 morphology of the S1 fibers after 2h in an acid medium (Figure 8) indicates that it is possible
440 for small molecules to permeate through the shell, since it is believed that water ingress led
441 to this destruction. The fiber breakages observed will accelerate drug release by exposing
442 some of the core to the dissolution medium, but this should be a relatively small effect
443 given the small area of the core revealed in this manner. It should be noted that polymer
444 solubility is no predictor of the rate of release, nor how much will release at pH 1.0: the S1
445 fibers with a PVP core show much less release in acidic conditions than the S3 fibers (ES-100
446 core).

447

448 Although substantial release is observed in the pH 1.0 medium, the fibers prepared in this
449 work nevertheless show interesting two-stage release profiles. *In vivo*, this would be
450 expected to yield some release in the stomach and more subsequently lower in the GI tract.
451 The balance between these stages can be tuned by varying the polymer composition in the
452 core. Such two-stage release profiles are much sought after in pharmaceuticals, and may have
453 utility for the treatment of colorectal cancer.

454

455 **5. Conclusions**

456 A series of 5-fluorouracil (5-FU) loaded electrospun fibers was prepared in this work: four
457 core/shell materials with a Eudragit S100 (ES-100) shell and a drug-loaded core, and one
458 monolithic fiber material in which ES-100 comprised the filament-forming polymer. The
459 fibers were smooth and cylindrical in shape, and the core/shell materials clearly showed two
460 distinct phases in transmission electron microscopy. The active ingredient existed in the
461 amorphous form in the fibers. In contrast to previous literature reports, very significant
462 amounts of drug release (around 30 – 80 % of maximum release) were seen during
463 immersion in a pH 1.0 medium, despite the insolubility of ES-100 below pH 7.0. Inspection
464 by electron microscopy of the fibers after 2h in pH 1.0 showed that when the core polymer
465 was poly(vinyl pyrrolidone) the individual fibers had merged to form a film, while fibers with
466 cores of ES-100 or drug alone were observed to have snapped and broken up into smaller
467 parts in places. The monolithic ES-100 fibers additionally showed breakages. It is proposed
468 that the low molecular weight of 5-FU permitted it to diffuse through pores in the ES-100
469 coating, with the high acid solubility of the drug providing a thermodynamic driver for this
470 to happen. In addition, the loss of fiber integrity observed is expected to provide additional
471 escape routes for the 5-FU. The fiber formulations thus show two very distinct phases of
472 release, with burst release immediately after immersion into a stomach-mimicking
473 environment, and a second burst of release upon transfer into a pH 6.8 buffer imitating the
474 small intestine.

475

476 **6. Acknowledgements**

477 This work was supported by the China NSFC/UK Royal Society cost share international
478 exchanges scheme (No. 51411130128/IE131748) and the National Science Foundation of
479 China (No. 51373101). The authors would like to thank Mr David McCarthy for recording
480 TEM images, Mrs Kate Keen for SEM data, Professor Abdul Basit and Dr Alvaro Goyanes for
481 helpful discussions.

482

483 **7. References**

484 Abdullah, G.Z., Abdulkarim, M.F., Chitneni, M., Mutee, A.F., Ameer, O.Z., Salman, I.M., Noor, A.M.,
485 2011. Preparation and in vitro evaluation of mebeverine HCl colon-targeted drug delivery system.
486 Pharm. Dev. Tech 16, 331-342.

- 487 Aguilar, L.E., Unnithan, A.R., Amarjargal, A., Tiwari, A.P., Hong, S.T., Park, C.H., Kim, C.S., 2015.
488 Electrospun polyurethane/Eudragit (R) L100-55 composite mats for the pH dependent release of
489 paclitaxel on duodenal stent cover application. *Int. J. Pharm* 478, 1-8.
- 490 Balogh, A., Farkas, B., Farago, K., Farkas, A., Wagner, I., Van Assche, I., Verreck, G., Nagy, Z.K.,
491 Marosi, G., 2015. Melt-blown and electrospun drug-loaded polymer fiber mats for dissolution
492 enhancement: a comparative study. *J. Pharm. Sci.* 104, 1767-1776.
- 493 Carr, D.A., Peppas, N.A., 2010. Assessment of poly(methacrylic acid-co-N-vinyl pyrrolidone) as a
494 carrier for the oral delivery of therapeutic proteins using Caco-2 and HT29-MTX cell lines. *J. Biomed.*
495 *Mater. Res.* 92A, 504-512.
- 496 Chakraborty, S., Liao, I.C., Adler, A., Leong, K.W., 2009. Electrohydrodynamics: A facile technique to
497 fabricate drug delivery systems. *Adv. Drug Del. Rev.* 61, 1043-1054.
- 498 Chawla, A., Sharma, P., Pawar, P., 2012. Eudragit S-100 coated sodium alginate microspheres of
499 naproxen sodium: formulation, optimization and in vitro evaluation. *Acta Pharm.* 62, 529-545.
- 500 Chen, H., Wang, N., Di, J., Zhao, Y., Song, Y., Jiang, L., 2010a. Nanowire-in-microtube structured
501 core/shell fibers via multifluidic coaxial electrospinning. *Langmuir* 26, 11291-11296.
- 502 Chen, P., Wu, Q.-S., Ding, Y.-P., Chu, M., Huang, Z.-M., Hue, W., 2010b. A controlled release system
503 of titanocene dichloride by electrospun fiber and its antitumor activity in vitro. *Eur. J. Pharm.*
504 *Biopharm.* 76, 413-420.
- 505 Gao, H., Gu, Y., Ping, Q., 2007. The implantable 5-fluorouracil-loaded poly(L-lactic acid) fibers
506 prepared by wet-spinning from suspension. *J. Controlled Release* 118, 325-332.
- 507 Hamori, M., Yoshimatsu, S., Hukuchi, Y., Shimizu, Y., Fukushima, K., Sugioka, N., Nishimura, A.,
508 Shibata, N., 2014. Preparation and pharmaceutical evaluation of nano-fiber matrix supported drug
509 delivery system using the solvent-based electrospinning method. *Int. J. Pharm.* 464, 243-251.
- 510 Hu, D., Liu, L., Chen, W., Li, S., Zhao, Y., 2012. A novel preparation method for 5-aminosalicylic acid
511 loaded Eudragit S100 nanoparticles. *Int. J. Mol. Sci.* 13, 6454-6468.
- 512 Illangakoon, U.E., Nazir, T., Williams, G.R., Chatterton, N.P., 2014. Mebeverine-loaded electrospun
513 nanofibers: Physicochemical characterization and dissolution studies. *J. Pharm. Sci.* 103, 283-292.
- 514 Kaassis, A.Y.A., Young, N., Sano, N., Merchant, H.A., Yu, D.G., Chatterton, N.P., Williams, G.R., 2014.
515 Pulsatile drug release from electrospun poly(ethylene oxide)-sodium alginate blend nanofibres. *J.*
516 *Mater. Chem. B* 2, 1400-1407.
- 517 Karthikeyan, K., Guhathakarta, S., Rajaram, R., Korrapati, P.S., 2012. Electrospun zein/eudragit
518 nanofibers based dual drug delivery system for the simultaneous delivery of aceclofenac and
519 pantoprazole. *Int. J. Pharm.* 438, 117-122.

- 520 Krishnaiah, Y.S.R., Satyanarayana, V., Dinesh Kumar, B., Karthikeyan, R.S., 2002. In vitro drug release
521 studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. *Eur. J. Pharm.*
522 *Biopharm.* 16, 185-192.
- 523 Li, X., Kanjwal, M.A., Lin, L., Chronakis, I.S., 2013a. Electrospun polyvinyl-alcohol nanofibers as oral
524 fast-dissolving delivery system of caffeine and riboflavin. *Colloids Surf. B* 103, 182-188.
- 525 Li, X., Lin, L., Zhu, Y., Liu, W., Yu, T., Ge, M., 2013b. Preparation of ultrafine fast-dissolving
526 cholecalciferol-loaded poly(vinyl pyrrolidone) fiber mats via electrospinning. *Polym. Composite.* 34,
527 282-287.
- 528 Llorens, E., Ibanez, H., Del Valle, L.J., Puiggali, J., 2015. Biocompatibility and drug release behavior of
529 scaffolds prepared by coaxial electrospinning of poly(butylene succinate) and polyethylene glycol.
530 *Mater. Sci. Eng. C Mater. Biol. Appl.* 49, 472-484.
- 531 Lowman, A.M., Morishita, M., Kajita, M., Nagai, T., Peppas, N.A., 1999. Oral delivery of insulin using
532 pH-responsive complexation gels. *J. Pharm. Sci.* 88, 933-937.
- 533 Momoh, M.A., Kenekwue, F.C., Nnamani, P.O., Umetiti, J.C., 2014. Influence of magnesium
534 stearate on the physicochemical and pharmacodynamic characteristics of insulin-loaded Eudragit
535 entrapped mucoadhesive microspheres. *Drug delivery*, DOI:
536 10.3109/10717544.10712014.10898108.
- 537 Nagy, Z.K., Nyul, K., Wagner, I., Molnar, K., Marosi, G., 2010. Electrospun water soluble polymer mat
538 for ultrafast release of donepezil HCl. *Express Polym. Lett.* 4, 763-772.
- 539 Nista, S.V.G., D'Ávila, M.A., Martinez, E.F., Silva, A.d.S.F., Mei, L.H.I., 2013. Nanostructured
540 membranes based on cellulose acetate obtained by electrospinning. Part II. Controlled release
541 profile and microbiological behavior. *J. Appl. Polym. Sci.* 130, 2772-2779.
- 542 Okuda, T., Tominaga, K., Kidoaki, S., 2010. Time-programmed dual release formulation by
543 multilayered drug-loaded nanofiber meshes. *J. Controlled Release* 143, 258-264.
- 544 Rejinold, N.S., Muthunayanan, M., Chennazhi, K.P., Nair, S.V., Jayakumar, R., 2011. 5-Fluorouracil
545 loaded fibrinogen nanoparticles for cancer drug delivery applications. *Int. J. Biol. Macromol.* 48, 98-
546 105.
- 547 Ritger, P.L., Peppas, N.A., 1986. A simple equation for description of solute release II. Fickian and
548 anomalous release from swellable devices. *J. Controlled Release* 5, 37-42.
- 549 Samprasit, W., Akkaramongkolporn, P., Ngawhirunpat, T., Rojanarata, T., Kaomongkolgit, R.,
550 Opanasopit, P., 2015. Fast releasing oral electrospun PVP/CD nanofiber mats of taste-masked
551 meloxicam. *Int. J. Pharm.* 487, 213-222.
- 552 Shen, X., Yu, D., Zhu, L., Branford-White, C., White, K., Chatterton, N.P., 2011. Electrospun diclofenac
553 sodium loaded Eudragit (R) L 100-55 nanofibers for colon-targeted drug delivery. *Int. J. Pharm.* 408,
554 200-207.

- 555 Varshosaz, J., Minaiyan, M., Khaleghi, N., 2015. Eudragit nanoparticles loaded with silybin: a detailed
556 study of preparation, freeze-drying condition and in vitro/in vivo evaluation. *J. Microencapsul.*, DOI:
557 10.3109/02652048.02652014.02995728.
- 558 Williams, G.R., Chatterton, N.P., Nazir, T., Yu, D.-G., Zhu, L.-M., Branford-White, C.J., 2012.
559 Electrospun nanofibers in drug delivery: recent developments and perspectives. *Therap. Del.* 3, 515-
560 533.
- 561 Xie, J., Wang, C.-H., 2006. Electrospun micro- and nanofibers for sustained delivery of paclitaxel to
562 treat C6 glioma in vitro. *Pharm. Res.* 23, 1817-1826.
- 563 Xu, J., Jiao, Y., Shao, X., Zhou, C., 2011. Controlled dual release of hydrophobic and hydrophilic drugs
564 from electrospun poly (l-lactic acid) fiber mats loaded with chitosan microspheres. *Mater. Lett.* 65,
565 2800-2803.
- 566 Xu, Q., Zhang, N., Qin, W., Liu, J., Jia, Z., Liu, H., 2013. Preparation, in vitro and in vivo evaluation of
567 budesonide loaded core/shell nanofibers as oral colonic drug delivery system. *J. Nanosci.*
568 *Nanotechnol.* 13, 149-156.
- 569 Yu, D.-G., Liu, F., Cui, L., Liu, Z.-P., Wang, X., Bligh, S.W.A., 2013a. Coaxial electrospinning using a
570 concentric Teflon spinneret to prepare biphasic-release nanofibers of helicid. *RSC Adv.* 3, 17775.
- 571 Yu, D.-G., Xu, Y., Li, Z., Du, L.-P., Zhao, B.-G., Wang, X., 2014. Coaxial electrospinning with mixed
572 solvents: From flat to round Eudragit L100 nanofibers for better colon-targeted sustained drug
573 release profiles. *J. Nanomater.* 2014, 8.
- 574 Yu, D.G., Williams, G.R., Wang, X., Liu, X.K., Li, H.L., Bligh, S.W.A., 2013b. Dual drug release
575 nanocomposites prepared using a combination of electro spraying and electrospinning. *RSC Adv.* 3,
576 4652-4658.
577